The global burden of gout: estimates from the Global Burden of Disease 2010 study
by Global MusculoskeletalObjective: Gout is the most common cause of inflammatory arthritis in men, but has not previously been included in Global Burden of Disease (GBD) studies. As part of the GBD 2010 Study, the Musculoskeletal Disorders and Risk Factors Expert Group estimated the global burden of gout.
The global burden of other musculoskeletal disorders: estimates from the Global Burden of Disease 2010 study
by Global MusculoskeletalObjective: To estimate disability from the remainder of musculoskeletal (MSK) disorders (categorised as other MSK) not covered by the estimates made specifically for osteoarthritis (OA), rheumatoid arthritis (RA), gout, low back pain and neck pain, as part of the Global Burden of Disease (GBD) 2010 study.
The global burden of hip and knee osteoarthritis: estimates from the Global Burden of Disease 2010 study
by Global MusculoskeletalObjective: To estimate the global burden of hip and knee osteoarthritis (OA) as part of the Global Burden of Disease 2010 study and to explore how the burden of hip and knee OA compares with other conditions.
The global burden of rheumatoid arthritis: estimates from the Global Burden of Disease 2010 study
by Global MusculoskeletalObjectives: To estimate the global burden of rheumatoid arthritis (RA), as part of the Global Burden of Disease 2010 study of 291 conditions and how the burden of RA compares with other conditions.
The global burden of musculoskeletal conditions for 2010: an overview of methods
by Global MusculoskeletalThe objective of this paper is to provide an overview of methods used for estimating the burden from musculoskeletal (MSK) conditions in the Global Burden of Diseases 2010 study. It should be read in conjunction with the disease-specific MSK papers published in Annals of Rheumatic Diseases.
The global burden of neck pain: estimates from the Global Burden of Disease 2010 study
by Global MusculoskeletalObjective: To estimate the global burden of neck pain.
Reflecting on the global burden of musculoskeletal conditions: lessons learnt from the Global Burden of Disease 2010 Study and the next steps forward
by Global MusculoskeletalThe objective of this paper is to provide an overview of the strengths, limitations and lessons learned from estimating the burden from musculoskeletal (MSK) conditions in the Global Burden of Disease 2010 Study (GBD 2010 Study). It should be read in conjunction with the other GBD 2010 Study papers published in this journal. The strengths of the GBD 2010 Study include: the involvement of a MSK expert group; development of new and more valid case definitions, functional health states, and disability weights to better reflect the MSK conditions; the extensive series of systematic reviews undertaken to obtain data to derive the burden estimates; and the use of a new, more advanced version of the disease-modelling software (DisMod-MR). Limitations include: many regions of the world did not have data; the extent of heterogeneity between included studies; and burden does not include broader aspects of life, such as participation and well-being. A number of lessons were learned. Ongoing involvement of experts is critical to ensure the success of future efforts to quantify and monitor this burden. A paradigm shift is urgently needed among global agencies in order to alleviate the rapidly increasing global burden from MSK conditions. Prevention and control of MSK disability are required, along with health system changes. Further research is needed to improve understanding of the predictors and clinical course across different settings, and the ways in which MSK conditions can be better managed and prevented.
Epidemiology: Measurement matters—making musculoskeletal disease count
by Global MusculoskeletalReliable estimates of disease burden support rational allocation of financial and human resources. Measurement is a powerful force for change as 'what gets measured gets done'. The global burden of musculoskeletal disease studies ensures visibility of these highly prevalent, disabling diseases. Now we must act to reduce disease burden.